TEP et tumeurs endocrines

Rigo, Pierre; Belhocine, Tarik; Hustinx, Roland; Foidart, Jacqueline

Request a copy

Article (Scientific journals)

TEP et tumeurs endocrines

Rigo, Pierre; Belhocine, Tarik; Hustinx, Roland et al.

2000 • In Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique, 24 (5), p. 275-282

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/19011

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Rigo P et al, Méd Nucl Imag Fonct Metab 2000.pdf

Publisher postprint (3.01 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

FDG; Positron emission tomography; Oncology; Endocrine tumors

Abstract :

[fr] Les auteurs passent en revue les indications de la TEP et en particulier du 18FDG dans l'évaluation des diverses tumeurs endocrines de la thyroïde, des parathyroïdes, des surrénales et de l'hyophyse. Les tumeurs neuroendocrines, gastroentéropancréatiques et carcinoïdes, sont également analysées. Habituellement, les tumeurs différenciées ayant une faible activité métabolique et proliférative, elles ne fixent que peu le FDG. Dans l'évaluation des tumeurs endocrines, la TEP au FDG n'intervient en général pas en première intention mais elle joue un rôle complémentaire d'autres scintigraphies spécifiques.

Disciplines :

Oncology
Radiology, nuclear medicine & imaging

Author, co-author :

Rigo, Pierre ; Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire

Belhocine, Tarik

Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire

Foidart, Jacqueline ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire

Language :

French

Title :

TEP et tumeurs endocrines

Publication date :

2000

Journal title :

Médecine Nucléaire: Imagerie Fonctionnelle et Métabolique

ISSN :

0928-1258

eISSN :

1878-6820

Publisher :

Elsevier, Paris, France

Volume :

Issue :

Pages :

275-282

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 January 2010

Statistics

Number of views

79 (4 by ULiège)

Number of downloads

2 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Bloom A.D., Adler L.P., Shuck J.M. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993; 114: 728-734.
Adler L.P., Bloom A.D. Positron emission tomography of thyroid masses. Thyroid 1993; 3: 195-200.
Joenssu H., Ahonen A., Klemi P.J. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur J Nucl Med 1998; 13: 502-506.
Wang W., Macapinlac H., Larson S.M. et al. (18F)-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84: 2291-2302.
Schlumberger M.J. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.
Wong CO, Dworkin HJ. Role of FDG PET in metastatic thyroid cancer. J Nucl Med 1999; 40: 993-994.
Grunwald F., Kalicke T., Feine U. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer : results of a multicentre study. Eur J Nucl Med 1999; 26: 1547-1552.
Chung J.K., So Y., Lee J.S. et al. Value of FDG PET in papillary carcinoma with negative 131I whole-body scan. J Nucl Med 1999; 40: 986-992.
Seabold J.E., Gurll N., Schurrer M.E. et al. Comparison of 99mYc-methoxyisobutyl isonitril and 201 Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy. J Nucl Med 1999; 40: 1434-1440.
Grunwald F., Menzel C., Bender H. et al. Comparison of 18FDG-PET with 131 iodine and 99mTc-ses scintigraphy in differentiated cancer. Thyroid 1997; 7: 327-335.
Feine U. Fluor-18-deoxyglycose positron emission tomography in differentiated thyroid cancer. Eur J Endocrinol 1998; 138: 492-496.
Moog F., Linke R., Tiling R. et al. The influence of TSH levels on the uptake of F-18-FDG in metastatic thyroid carcinoma. Eur J Nucl Med 1999; 26: 1014 (abstract).
Maisey M.M., Wahl R.L., Barrington SF. Atlas of clinical positron emission tomography Arnold, London, 1999.
Gasparani P., Rubella D., Ferlin G. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 1997; 20: 527-530.
Neumann D.R., Esselstyn C.B., MacIntyre W.J. et al. Primary hyperparathyroidism : preoperative parathyroid imaging with regional body FDG PET. Radiology 1994; 192: 509-512.
Neumann D.R., Esselstyn C.B., Kim E.Y. Recurrent posdtoperative parathyroid carcinoma : FDG-PET and sestamibi-SPECT findings. J Nucl Med 1996; 37: 2000-2001.
Melon P., Luxen A., Hamoir E., Meurisse M. Fluorine-18-fluorodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism. Eur J Nucl Med 1995; 22: 556-558.
Sundin A., Johansson C., Hellman P. et al. PET and parathyroid L-(carbon-11) methionine acculumation in hyperparathyroidism. J Nucl Med 1996; 37: 1766-1770.
Cook G.J.R., Wong J.C.H., Smellie WJB et al. 11C-methionine PET for patients with persistent or recurrent hyperparathyroidism after surgery. Eur J Endocrinol 1998; 139: 195-197.
Shulkin B.L., Koeppe R.A., Francis I.R. et al. Pheochromocytomas that do not accumulate metaiodobenzylguanidine : localisation with PET and administration of FDG. Radiology 1993; 186: 711-715.
Shulkin B.L., Thompson N.W., Shapiro B. et al. Pheochromocytomas : Imaging with 2-{Fluorine- 18}fluoro-2-deoxy-D-glucose PET. Radiology 1999; 212: 35-41.
Maurea S., Mainolfi C., Bazzicalupo L. et al. Imaging of adrenal tumors using FDG-PET : comparison of benign and malignant lesions. AJR 1999; 173: 25-29.
Erasmus J.J., Patz E.F.Jr, Page McAdamms H et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR 1997; 168: 1357-1360.
Erasmus J.J., Page McAdams H., Patz E.F.Jr et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR 1998; 170: 1369-1373.
Boland G.W., Goldberg M.A., Lee M.J. et al. Indeterminate adrenal mass in patients with cancer : evaluation at PET with 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1995; 194: 131-134.
Lamki L.M. Positron emission tomography, bronchogenix carcinoma and the adrenals. AJR 1997; 168: 1361-1362.
Adams S., Baum R., Rink T. et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25: 79-83.
Adams S., Baum R.P., Hertel A. et al. Metabolic (PET) and receptor (SPEET) imaging of well- and less well-differentiated tumours : comparison with the expression of the Ki-67 antigen. Nucl Med Com 1998; 19: 641-647.
Pasquali C., Rubello D., Sperti C. et al. Neuroendocrine tumor imaging : 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 1998; 22: 588-592.
Kulke M.H., Mayer R.J. Carcinoid tumors. N Engl J Med 1999; 340: 858-868.
Ahlström H., Eriksson B., Bergström M. et al. Pancreatic neuroendocrine tumors : diagnosis with PET. Radiology 1995; 195: 333-337.
De Souza B., Brunetti A., Fulham M.J. et al. Pituitary microadenomas : a PET study. Radiology 1990; 177: 39-44.